{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:43:29Z","timestamp":1793396609681,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","award":["#F-12625"],"award-info":[{"award-number":["#F-12625"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Folke Hermansen Fund for Cancer Research"},{"name":"University of Stavanger & Stavanger University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cachexia is associated with worse postoperative outcomes, but the added role of neoadjuvant therapy (NAT) is unclear. This study evaluated whether preoperative cachexia and NAT act as a \u201cdouble jeopardy\u201d after pancreatoduodenectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A nationwide observational cohort study was conducted using the Norwegian NORGAST registry (2016\u20132023). Adults undergoing pancreatoduodenectomy for malignancy were included. Cachexia was defined by consensus weight-loss criteria. Modified Poisson and Cox models (with a cachexia and NAT interaction term) estimated adjusted risk ratios (aRR) for textbook outcome (TO), prolonged length-of-stay (LOS), and adjusted hazard ratios (aHR) for overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1424 patients undergoing pancreatoduodenectomy, cachexia was present in 588 (41.3%). Having cachexia was associated with higher TO (aRR 1.28, 95% CI 1.13\u20131.46) with effect modification by body mass index (BMI) (interaction\n                      <jats:italic>P<\/jats:italic>\n                      = 0.047). Patients with cachexia had a lower risk of prolonged LOS (aRR 0.64, 95% CI 0.51\u20130.80). Cachexia was not independently associated with overall survival (aHR 1.15, 95% CI 0.97\u20131.36). NAT was associated with a higher hazard of death (aHR 1.44, 95% CI 1.09\u20131.92), likely reflecting confounding by indication. No statistically significant interaction between cachexia and NAT was observed for TO (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.277) or for survival (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.863).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preoperative cachexia was associated with higher rates of TO. Higher TO was attributed to patients with overweight or obesity, to a shorter index stay, and more frequent transfers to a secondary facility, but not fewer complications. Cachexia was not associated with worse long-term survival, and a \u201cdouble jeopardy\u201d between cachexia and receiving NAT was not found.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18941-y","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:24:18Z","timestamp":1767572658000},"page":"3563-3575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined Impact of Neoadjuvant Therapy and Preoperative Cachexia in Patients Undergoing Pancreatoduodenectomy: Is There a \u201cDouble Jeopardy\u201d? A National Cohort Study Investigating the Association with Short- and Long-Term Outcomes"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-4412","authenticated-orcid":false,"given":"Marcus Thomas Thor","family":"Roals\u00f8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Oanaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herish","family":"Garresori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Hestnes","family":"Edland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild","family":"Dalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne R\u00f8land","family":"Hagland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"S\u00f8reide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"5","key":"18941_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol."},{"issue":"11","key":"18941_CR2","doi-asserted-by":"publisher","first-page":"e476","DOI":"10.1016\/S1470-2045(13)70172-4","volume":"14","author":"W Hartwig","year":"2013","unstructured":"Hartwig W, Werner J, J\u00e4ger D, Debus J, B\u00fcchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14(11):e476\u201385. https:\/\/doi.org\/10.1016\/S1470-2045(13)70172-4.","journal-title":"Lancet Oncol."},{"issue":"3","key":"18941_CR3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1245\/s10434-021-10995-y","volume":"29","author":"H Rom","year":"2022","unstructured":"Rom H, Tamir S, Van Vugt JLA, et al. Sarcopenia as a predictor of survival in patients with pancreatic adenocarcinoma after pancreatectomy. Ann Surg Oncol. 2022;29(3):1553\u201363. https:\/\/doi.org\/10.1245\/s10434-021-10995-y.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"18941_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.21037\/hbsn.2019.02.05","volume":"8","author":"P Seika","year":"2019","unstructured":"Seika P, Klein F, Pelzer U, Pratschke J, Bahra M, Malinka T. Influence of the body mass index on postoperative outcome and long-term survival after pancreatic resections in patients with underlying malignancy. Hepatobiliary Surg Nutr. 2019;8(3):201\u201310. https:\/\/doi.org\/10.21037\/hbsn.2019.02.05.","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"3 Suppl 1","key":"18941_CR5","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.surg.2012.05.028","volume":"152","author":"T Pausch","year":"2012","unstructured":"Pausch T, Hartwig W, Hinz U, et al. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. Surgery. 2012;152(3 Suppl 1):S81-88. https:\/\/doi.org\/10.1016\/j.surg.2012.05.028.","journal-title":"Surgery."},{"key":"18941_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clnu.2025.02.014","volume":"47","author":"Y Fugane","year":"2025","unstructured":"Fugane Y, Tanaka S, Mizuno Y, et al. Prognostic impact of preoperative cachexia in patients undergoing major hepatopancreatobiliary surgery for malignancy. Clin Nutr. 2025;47:112\u20138. https:\/\/doi.org\/10.1016\/j.clnu.2025.02.014.","journal-title":"Clin Nutr."},{"key":"18941_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2022.111660","volume":"99\u2013100","author":"Y Aoki","year":"2022","unstructured":"Aoki Y, Furukawa K, Suzuki D, et al. Influence of sarcopenia as defined by EWGSOP2 on complications after pancreaticoduodenectomy and on the prognosis of pancreatic head cancer: a prospective cohort study. Nutr Burbank Los Angel Cty Calif. 2022;99\u2013100:111660. https:\/\/doi.org\/10.1016\/j.nut.2022.111660.","journal-title":"Nutr Burbank Los Angel Cty Calif."},{"key":"18941_CR8","doi-asserted-by":"publisher","first-page":"107327482412927","DOI":"10.1177\/10732748241292784","volume":"31","author":"MA Khalil","year":"2024","unstructured":"Khalil MA, Jafri SAA, Zahra Naqvi ME, et al. Impact of cachexia on chemotherapy efficacy and survival in pancreatic cancer: a systematic review and meta-analysis. Cancer Control. 2024;31:10732748241292784. https:\/\/doi.org\/10.1177\/10732748241292784.","journal-title":"Cancer Control."},{"issue":"2","key":"18941_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jcsm.12155","volume":"8","author":"DPJ van Dijk","year":"2017","unstructured":"van Dijk DPJ, Bakens MJAM, Coolsen MME, et al. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8(2):317\u201326. https:\/\/doi.org\/10.1002\/jcsm.12155.","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"12","key":"18941_CR10","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.hpb.2020.04.004","volume":"22","author":"Y Ryu","year":"2020","unstructured":"Ryu Y, Shin SH, Kim JH, et al. The effects of sarcopenia and sarcopenic obesity after pancreaticoduodenectomy in patients with pancreatic head cancer. HPB. 2020;22(12):1782\u201392. https:\/\/doi.org\/10.1016\/j.hpb.2020.04.004.","journal-title":"HPB."},{"issue":"9","key":"18941_CR11","doi-asserted-by":"publisher","first-page":"10438","DOI":"10.1002\/cam4.5779","volume":"12","author":"X Shen","year":"2023","unstructured":"Shen X, Wang X, Zheng Z, et al. The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: a retrospective study based on a large population. Cancer Med. 2023;12(9):10438\u201348. https:\/\/doi.org\/10.1002\/cam4.5779.","journal-title":"Cancer Med."},{"key":"18941_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01965","author":"IM Chen","year":"2025","unstructured":"Chen IM, Johansen JS, Theile S, et al. Randomized phase II study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in advanced pancreatic cancer: survival and cachexia. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.23.01965.","journal-title":"J Clin Oncol"},{"issue":"3","key":"18941_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.CCR-23-1631","volume":"30","author":"J Crawford","year":"2024","unstructured":"Crawford J, Calle RA, Collins SM, et al. A phase Ib first-in-patient study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponsegromab in participants with cancer and cachexia. Clin Cancer Res. 2024;30(3):489\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1631.","journal-title":"Clin Cancer Res."},{"issue":"23","key":"18941_CR14","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","volume":"125","author":"S Hamauchi","year":"2019","unstructured":"Hamauchi S, Furuse J, Takano T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019;125(23):4294\u2013302. https:\/\/doi.org\/10.1002\/cncr.32406.","journal-title":"Cancer."},{"issue":"10485","key":"18941_CR15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, et al. Pancreatic cancer. Lancet. 2025;405(10485):1182\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(25)00261-2.","journal-title":"Lancet."},{"issue":"3","key":"18941_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","volume":"9","author":"KJ Labori","year":"2024","unstructured":"Labori KJ, Bratlie SO, Andersson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9(3):205\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(23)00405-3.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"9","key":"18941_CR17","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","volume":"8","author":"MHG Katz","year":"2022","unstructured":"Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2319.","journal-title":"JAMA Oncol."},{"issue":"11","key":"18941_CR18","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220\u201330. https:\/\/doi.org\/10.1200\/JCO.21.02233.","journal-title":"J Clin Oncol."},{"issue":"4","key":"18941_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/jcsm.12307","volume":"9","author":"JK Kays","year":"2018","unstructured":"Kays JK, Shahda S, Stanley M, et al. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9(4):673\u201384. https:\/\/doi.org\/10.1002\/jcsm.12307.","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"3","key":"18941_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1457496918766697","volume":"107","author":"K Lassen","year":"2018","unstructured":"Lassen K, Nymo LS, K\u00f8rner H, et al. The New National Registry for Gastrointestinal Surgery in Norway: NoRGast. Scand J Surg SJS Off Organ Finn Surg Soc Scand Surg Soc. 2018;107(3):201\u20137. https:\/\/doi.org\/10.1177\/1457496918766697.","journal-title":"Scand J Surg SJS Off Organ Finn Surg Soc Scand Surg Soc."},{"key":"18941_CR21","unstructured":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology in: Journal of the National Comprehensive Cancer Network Volume 19 Issue 4 (2021). Accessed May 9, 2025. https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/4\/article-p439.xml"},{"issue":"3","key":"18941_CR22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jamcollsurg.2009.12.004","volume":"210","author":"MR Porembka","year":"2010","unstructured":"Porembka MR, Hall BL, Hirbe M, Strasberg SM. Quantitative weighting of postoperative complications based on the accordion severity grading system: demonstration of potential impact using the american college of surgeons national surgical quality improvement program. J Am Coll Surg. 2010;210(3):286\u201398. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2009.12.004.","journal-title":"J Am Coll Surg."},{"issue":"1","key":"18941_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/SLA.0000000000003451","volume":"271","author":"S van Roessel","year":"2020","unstructured":"van Roessel S, Mackay TM, van Dieren S, et al. Textbook outcome: nationwide analysis of a novel quality measure in pancreatic surgery. Ann Surg. 2020;271(1):155. https:\/\/doi.org\/10.1097\/SLA.0000000000003451.","journal-title":"Ann Surg."},{"key":"18941_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03.","journal-title":"J Stat Softw."},{"issue":"1","key":"18941_CR25","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","volume":"13","author":"DD Sjoberg","year":"2021","unstructured":"Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible summary tables with the gtsummary package. R J. 2021;13(1):570. https:\/\/doi.org\/10.32614\/RJ-2021-053.","journal-title":"R J."},{"issue":"4","key":"18941_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377\u201399. https:\/\/doi.org\/10.1002\/sim.4067.","journal-title":"Stat Med."},{"key":"18941_CR27","doi-asserted-by":"publisher","unstructured":"Rubin DB. Multiple Imputation for Nonresponse in Surveys. 1st ed. Wiley; 1987. https:\/\/doi.org\/10.1002\/9780470316696","DOI":"10.1002\/9780470316696"},{"issue":"282","key":"18941_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u201381. https:\/\/doi.org\/10.1080\/01621459.1958.10501452.","journal-title":"J Am Stat Assoc."},{"issue":"2","key":"18941_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Ser B Methodol. 1972;34(2):187\u2013202. https:\/\/doi.org\/10.1111\/j.2517-6161.1972.tb00899.x.","journal-title":"J R Stat Soc Ser B Methodol."},{"issue":"1","key":"18941_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239\u201341. https:\/\/doi.org\/10.1093\/biomet\/69.1.239.","journal-title":"Biometrika."},{"issue":"4","key":"18941_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/bjs5.67","volume":"2","author":"K Lassen","year":"2018","unstructured":"Lassen K, Nymo LS, Olsen F, S\u00f8reide K. Benchmarking of aggregated length of stay after open and laparoscopic surgery for cancers of the digestive system. BJS Open. 2018;2(4):246\u201353. https:\/\/doi.org\/10.1002\/bjs5.67.","journal-title":"BJS Open."},{"issue":"5","key":"18941_CR32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.surg.2018.05.040","volume":"164","author":"L Gianotti","year":"2018","unstructured":"Gianotti L, Besselink MG, Sandini M, et al. Nutritional support and therapy in pancreatic surgery: a position paper of the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2018;164(5):1035\u201348. https:\/\/doi.org\/10.1016\/j.surg.2018.05.040.","journal-title":"Surgery."},{"issue":"3","key":"18941_CR33","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1152\/physrev.00029.2024","volume":"105","author":"A Jaitovich","year":"2025","unstructured":"Jaitovich A, Hall JB. The flux of energy in critical illness and the obesity paradox. Physiol Rev. 2025;105(3):1487\u2013552. https:\/\/doi.org\/10.1152\/physrev.00029.2024.","journal-title":"Physiol Rev."},{"issue":"12","key":"18941_CR34","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539\u201347. https:\/\/doi.org\/10.1200\/JCO.2012.45.2722.","journal-title":"J Clin Oncol."},{"issue":"2","key":"18941_CR35","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1245\/s10434-024-16527-8","volume":"32","author":"NH Soh","year":"2025","unstructured":"Soh NH, Yau CRZ, Low XZ, et al. Prehabilitation outcomes in surgical oncology patients undergoing major abdominal surgery: a meta-analysis of randomized control trials. Ann Surg Oncol. 2025;32(2):1236\u201347. https:\/\/doi.org\/10.1245\/s10434-024-16527-8.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"18941_CR36","doi-asserted-by":"publisher","first-page":"8340","DOI":"10.1245\/s10434-024-15975-6","volume":"31","author":"EJ Yee","year":"2024","unstructured":"Yee EJ, Torphy RJ, Myers EK, et al. Dynamic anthropometrics in pancreatic cancer: associations between body composition changes during neoadjuvant therapy and survival outcomes after resection. Ann Surg Oncol. 2024;31(12):8340\u201351. https:\/\/doi.org\/10.1245\/s10434-024-15975-6.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"18941_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/jamasurg.2018.0979","volume":"153","author":"M Sandini","year":"2018","unstructured":"Sandini M, Pati\u0148o M, Ferrone CR, et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg. 2018;153(9):809\u201315. https:\/\/doi.org\/10.1001\/jamasurg.2018.0979.","journal-title":"JAMA Surg."},{"issue":"6","key":"18941_CR38","doi-asserted-by":"publisher","first-page":"zrad137","DOI":"10.1093\/bjsopen\/zrad137","volume":"7","author":"I Farnes","year":"2023","unstructured":"Farnes I, Kleive D, Verbeke CS, et al. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2). BJS Open. 2023;7(6):zrad137. https:\/\/doi.org\/10.1093\/bjsopen\/zrad137.","journal-title":"BJS Open."},{"key":"18941_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/CLEP.S83839","volume":"7","author":"G Skeie","year":"2015","unstructured":"Skeie G, Borch K, Mode N, Henningsen M. Validity of self-reported body mass index among middle-aged participants in the Norwegian Women and Cancer study. Clin Epidemiol. 2015;7:313. https:\/\/doi.org\/10.2147\/CLEP.S83839.","journal-title":"Clin Epidemiol."},{"issue":"7","key":"18941_CR40","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s11605-008-0505-z","volume":"12","author":"J Bachmann","year":"2008","unstructured":"Bachmann J, Heiligensetzer M, Krakowski-Roosen H, B\u00fcchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2008;12(7):1193\u2013201. https:\/\/doi.org\/10.1007\/s11605-008-0505-z.","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract."},{"key":"18941_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-021-01301-4","volume":"124","author":"M Kordes","year":"2021","unstructured":"Kordes M, Larsson L, Engstrand L, L\u00f6hr M. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br J Cancer. 2021;124:1\u201314. https:\/\/doi.org\/10.1038\/s41416-021-01301-4.","journal-title":"Br J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18941-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18941-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18941-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:47:29Z","timestamp":1773330449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18941-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["18941"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18941-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Garresori has received honoraria from Ipsen, Amgen, Pfizer, Bristol Myers Squibb, AstraZeneca, Pierre Fabre, and Daiichi Sankyo for educational presentations or organizing multidisciplinary team meetings. The other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Data from the Norwegian Registry of Gastrointestinal Surgery (NORGAST) has been used in this publication. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by NORGAST is intended nor should it be inferred.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}